The use of decision-analytic models in Parkinsons disease: A systematic review and critical appraisal

Applied Health Economics and Health Policy

Volumn 9, Issue 4, 2011, Pages 243-258

  Shearer, James ^a   Green, Colin ^a   Counsell, Carl E ^b   Zajicek, John P ^c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Modelling; Parkinsons disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE;

AUTONOMIC DYSFUNCTION; DATA SYNTHESIS; DECISION ANALYTIC MODEL; DISEASE COURSE; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MORTALITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPSYCHIATRY; PARKINSON DISEASE; PRACTICE GUIDELINE; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; UNCERTAINTY;

DECISION SUPPORT TECHNIQUES; HUMANS; MODELS, STATISTICAL; PARKINSON DISEASE;

EID: 79959434098     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11590160-000000000-00000     Document Type: Review

References (64)

1. Samii A, Nutt J, Ransom B. Parkinsons disease. Lancet 2004; 363: 1783-93
2. Ibbotson T, Goa K. Management of Parkinsons disease: defining the role of entacapone. Dis Manage Health Outcomes 2002; 10 (10): 643-59 (Pubitemid 35216535)
3. Chaudhuri K, Healy D, Schapira A. Non-motor symptoms of Parkinsons disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45 (Pubitemid 43238347)
4. National Collaborating Centre for Chronic Conditions. Parkinsons disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006
5. Findley L, Aujila M, Bain P, et al. Direct economic impact of Parkinsons disease: a research survey of the UK. Mov Disord 2003; 18: 1139-45 (Pubitemid 37336937)
6. SculpherM, Claxton K, DrummondM, et al. Whither trialbased economic evaluation for health care decision making? Health Econ 2006; 15: 677-87
7. Weinstein M, OBrien BJ, Hornberger J, et al. Principles of good practice for decision-analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003; 6 (1): 9-17 (Pubitemid 36228345)
8. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
9. Siebert U, Bornscheim B, Walbert T, et al. Systematic assessment of decision models in Parkinsons disease. Value Health 2004; 7 (5): 610-26 (Pubitemid 39390841)
10. Eggert K, Reese J, Oertel W, et al. Cost effectiveness of pharmacotherapies in early Parkinsons disease. CNS Drugs 2008; 22 (10): 841-60
11. Nuijten M. Bridging decision analytic modelling with a cross-sectional study: application to Parkinsons disease. Pharmacoeconomics 2000; 17 (3): 227-36 (Pubitemid 30214630)
12. Goulionis J, Vozikis A. Medical decision making for patients with Parkinsons disease under average cost criterion. Aust New Zealand Health Policy 2009; 6 (15): 1-8
13. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355-71
14. Haycox A, Armand C, Murteira S, et al. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinsons disease in the UK setting: an economic Markov model evaluation. Drugs Aging 2009; 26 (9): 791-801
15. Kristiansen I, Bingefors K, Hyholm D, et al. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinsons disease in Sweden: an exploratory study. Appl Health Econ Health Policy 2009; 7 (3): 167-80
16. Hudry J, Rinne J, Keränen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinsons disease in Finland. Ann Pharmacother 2006; 40: 651-7
17. Findley L, Lees A, Apajasalo M, et al. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinsons disease patients with wearing-off. Curr Med Res Opin 2005; 21 (7): 1005-14 (Pubitemid 41032689)
18. Iskedjian M, Einarson T. Cost analysis of ropinerole versus levodopa in the treatment of Parkinsons disease. Pharmacoeconomics 2003; 21 (2): 115-27 (Pubitemid 36127007)
19. Lindgren P, Jönsson B, DuChane J. The cost-effectiveness of early cabergoline treatment compared to levodopa in Sweden. Eur J Health Econ 2003; 4: 37-42 (Pubitemid 36457055)
20. Smala A, Spottke E, Machat O, et al. Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord 2003; 18 (8): 898-905 (Pubitemid 37021164)
21. Palmer C, Nuijten M, Schmier J, et al. Cost effectiveness of treatment of Parkinsons disease with entacapone in the United States. Pharmacoeconomics 2002; 20 (9): 617-28
22. Linna M, Taimela E, Apajasalo M, et al. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinsons disease. Expert Rev Pharmacoecon Outcomes Res 2002; 2 (2): 91-7 (Pubitemid 34649779)
23. Nuijten M, van Iperen P, Palmer C, et al. Cost-effectiveness analysis of entacapone in Parkinsons disease: a Markov process analysis. Pharmacoeconomics 2001; 4 (4): 316-28 (Pubitemid 32756816)
24. Shimbo T, Hira K, Takemura M, et al. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinsons disease in Japan. Pharmacoeconomics 2001; 19 (8): 875-86 (Pubitemid 32758551)
25. Davey P, Rajan N, Lees M, et al. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinsons disease: a decision analytic model. Value Health 2001; 4 (4): 308-15 (Pubitemid 32756815)
26. Hoerger T, Bala M, Rowland C, et al. Cost effectiveness of pramipexole in Parkinsons disease in the US. Pharmacoeconomics 1998; 14 (5): 541-57 (Pubitemid 28512065)
27. Van Laere K, Everaert L, Annemans L, et al. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35: 1367-76
28. Antonini A, Berto P, Lopatriello S, et al. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and parkinsons disease in Italy. MovDisord 2008; 23 (15): 2202-9
29. Dodel R, Höffken H, Möller C, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinsons disease: a decision-analytic approach. Mov Disord 2003; 18 Suppl. 7: S52-62 (Pubitemid 37336929)
30. Hjelmgren J, Ghatnekar O, Reimer J, et al. Estimating the value of novel interventions for Parkinsons disease: an early decision-making model with application to dopamine cell replacement. Parkinsonism Relat Disord 2006; 12: 443-52 (Pubitemid 44416294)
31. Tomaszewski K, Holloway R. Deep brain stimulation in the treatment of Parkinsons disease: a cost-effectiveness analysis. Neurology 2001; 57: 663-71 (Pubitemid 32782995)
32. Sonnenberg FA, Beck JR. Markov models in medical decision making.Med Decis Making 1993 Dec 1; 13 (4): 322-38
33. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42
34. Fahn S, Elton R, UPDRS program members. Unified Parkinsons Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, et al., editors. Recent developments in Parkinsons disease. Florham Park (NJ): Macmillan Healthcare Information, 1987: 153-63
35. Palmer C, Schmier J, Snyder EH, et al. Patient preferences and utilities for off-time outcomes in the treatment of Parkinsons disease. Qual Life Res 2000; 9: 819-27 (Pubitemid 32209796)
36. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinsons disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19 (10): 1013-38 (Pubitemid 33701931)
37. Chrischilles E, Rubenstein L, Voelker M, et al. The health burdens of Parkinsons disease.Mov Disord 1998; 13 (3): 406-13
38. Keränen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9 (3): 163-8.
39. Schrag A, Jahanshahi M, Quinn N. How does Parkinsons disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15: 1112-8
40. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461-77 (Pubitemid 30398805)
41. Goetz C, Poewe W, Rascol O, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations the movement disorder society task force on rating scales for Parkinsons disease. Mov Disord 2004; 19 (9): 1020-8 (Pubitemid 39302834)
42. Movement Disorder Society Task Force on Rating Scales for Parkinsons Disease. The Unified Parkinsons Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18 (7): 738-50
43. DiRoccoA,Molinari S,KollmeierB, et al. Parkinsonsdisease: progression and mortality in the L-DOPA era. In: Battistin L, Scarlato T, Caraceni T, et al., editors. Advances in neurology. Philadelphia (PA): Lippincott-Raven Publishers, 1996: 3-11
44. Le Witt P. Levodopa for the treatment of Parkinsons disease. N Engl J Med 2008; 359 (23): 2468-76
45. Brennan A, Chick S, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15: 1295-310 (Pubitemid 44941606)
46. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004; 9 (2): 110-8 (Pubitemid 38568540)
47. Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health 2009; 12 (5): 739-49
48. Kim L, Thompson S. Uncertainty and validation of health economic decision models. Health Econ 2010; 19: 43-55
49. Poewe W. The natural history of Parkinsons disease. J Neurol 2006; 253 Suppl. 7: 2-6
50. Dowding C, Shenton C, Salek S. A review of the healthrelated quality of life and economic impact of Parkinsons disease. Drugs Aging 2006; 23 (9): 693-721 (Pubitemid 44536905)
51. Schrag A, Jahanshahi M, Quinn NP. What contributes to quality of life in patients with Parkinsonss disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-12 (Pubitemid 30636233)
52. Goetz C, Stebbins G. Risk factors for nursing home placement in advanced Parkinsons disease. Neurology 1993; 43: 2227-9 (Pubitemid 23346953)
53. van Rooden S, Visser M, Verbaan D, et al. Patterns of motor and non-motor features in Parkinsons disease. J Neurol Neurosurg Psychiatry 2009; 80: 846-50
54. Schapira AHV. Neurobiology and treatment of Parkinsons disease. Trends Pharmacol Sci 2009; 30 (1): 41-7
55. Post T, Freijer J, DeJongh J, et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22 (7): 1038-49 (Pubitemid 41127061)
56. Chan P, Holford N. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001; 41: 625-59 (Pubitemid 32385901)
57. Holford N, Chan P, Niutt J, et al. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33 (3): 281-311 (Pubitemid 44020383)
58. Guimaraes P, Kieburtz K, Goetz C, et al. Non-linearity of Parkinsons disease progression: implications for sample size calculations in clinical trials. Clin Trials 2005; 2: 509-18 (Pubitemid 43075658)
59. Clarke C. A cure for Parkinsons disease: can neuroprotection be proven with current trial designs? Mov Disord 2004; 19 (5): 491-8
60. Alves G, Forsaa EB, Pedersen KF, et al. Epidemiology of Parkinsons disease. J Neurol 2008; 22 Suppl. 5: 18-32
61. Jenkinson C, Fitzpatrick RAY, Peto VIV, et al. The Parkinsons Disease Questionnaire (PDQ-39): development and validation of a Parkinsons disease summary index score. Age Ageing 1997 Sep 1; 26 (5): 353-7 (Pubitemid 27448379)
62. Goetz C. Whats new? Clinical progression and staging of Parkinsons disease. J Neural Transm 2006; 70: 305-8 (Pubitemid 44622215)
63. van den Hout A, Matthews F. Estimating dementia-free life expectancy for Parkinsons patients using Bayesian inference and microsimulation. Biostatistics 2009; 10 (4): 729-43
64. Green C, Shearer J, Ritchie CW, et al. Model-based economic evaluation in Alzheimers disease: a review of the methods available to model Alzheimers disease progression. Value Health. In press